Skip to search formSkip to main contentSkip to account menu

FK-506

Known as: FK 506, FK506 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Abnormal release of Ca from sarcoplasmic reticulum (SR) via the cardiac ryanodine receptor (RyR2) may contribute to contractile… 
Review
1993
Review
1993
FK-506 and cyclosporin A (CsA) are potent immunosuppressive agents used clinically to prevent tissue rejection. Interest in the… 
Highly Cited
1992
Highly Cited
1992
ANTIGEN recognition by the T-cell receptor (TCR) initiates events including lymphokine gene transcription1, particularly… 
Review
1992
Review
1992
CsA, FK-506, and rapamycin are microbial products with potent immunosuppressive properties that result primarily from a selective… 
Highly Cited
1991
Highly Cited
1991
CYCLOSPORINA and FK506 inhibit T- and B-cell activation and other processes essential to an effective immune response1–3. In T… 
Highly Cited
1990
Highly Cited
1990
FK-506 and the structurally related macrolide rapamycin (RAP) were investigated in comparison with cyclosporin A (CsA) for their… 
Highly Cited
1990
Highly Cited
1990
The structurally related immunosuppressive macrolides FK-506 and rapamycin (RAP) were previously shown to inhibit T cell… 
Highly Cited
1989
Highly Cited
1989
CYCLOSPORIN A and the newly discovered immunosuppressant, FK-506, are potent inhibitors of T cell activation1. In addition to… 
Highly Cited
1987
Highly Cited
1987
FK-506, a novel immunosuppressant, has been isolated from the fermentation broth of Streptomyces tsukubaenis No. 9993 as… 
Highly Cited
1987
Highly Cited
1987
The immuno-pharmacological profile of a novel immunosuppressive agent, FK-506 produced by a streptomycete, is presented here. We…